Episode 2208: Brigham Buhler
Overview
In this October 1, 2024 episode, Joe Rogan hosts Brigham Buhler, founder of Ways2Well and co-founder of ReviveRx compounding pharmacy. Buhler positions himself as a pharmaceutical industry whistleblower who testified before the Senate about chronic disease and healthcare corruption. However, the episode fails to disclose critical information about Buhler’s own business practices, including a Class I FDA recall for mislabeled medications and ongoing legal issues with major pharmaceutical companies.
Key Issues
Undisclosed Conflicts of Interest
The most significant problem with this episode is the complete absence of critical context about Buhler’s business operations. While Buhler spends over three hours criticizing the pharmaceutical industry and promoting compounding pharmacies as safer alternatives, neither Rogan nor Buhler disclose:
Class I FDA Recall (April 2024): Just six months before this podcast, ReviveRx initiated a nationwide Class I recall - the FDA’s most severe category - because they mislabeled medication vials. Patients who believed they were receiving Tirzepatide (a diabetes and weight-loss medication) were actually sent testosterone cypionate (a hormone steroid). The FDA classified this as having “a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.”
FDA Inspection Violations (May 2022): FDA Form 483 documented that ReviveRx “may have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth” during an inspection of the Houston facility.
Active Litigation: Eli Lilly filed a federal lawsuit against ReviveRx in September 2023 (Case No. 4:23-cv-03521, Texas Southern District Court) for selling compounded versions of their medications. This lawsuit was ongoing at the time of the podcast.
Misleading Credentials
Buhler’s background is presented in a way that obscures his actual qualifications:
Business Background, Not Medical: Buhler graduated from the University of Houston Bauer College of Business, not pharmacy school or medical school. His career began as a pharmaceutical sales representative for Eli Lilly selling Cialis and antidepressants.
Self-Granted Pharmacy Titles: While Buhler has held titles like “Chief Pharmacy Officer” and “Non-Sterile Lead Pharmacist” at ReviveRx, these are titles at his own company rather than credentials earned through traditional pharmacy education and licensing.
This matters because listeners might reasonably assume someone running a pharmacy and making medical claims has formal pharmaceutical training, when his background is actually in sales and business.
Defense of Compounding While Omitting Safety Record
Buhler extensively defends compounding pharmacies against criticism, stating:
“Compounding pharmacies aren’t bad guys… every single ingredient they buy is an FDA approved ingredient, and every single compound they compound is sent off to an independent third party lab to verify.”
He contrasts this with big pharmaceutical companies that have “moved most of their manufacturing overseas, where the FDA has to submit before they can come do an inspection.”
What’s Missing: This defense would be more credible if Buhler acknowledged his own pharmacy’s Class I recall and FDA inspection violations. The fact that ingredients are FDA-approved is irrelevant when the final product is mislabeled - patients received testosterone instead of a diabetes medication.
GLP-1 Medication Claims
Buhler discusses compounded GLP-1 medications (semaglutide and tirzepatide) extensively, defending their safety and criticizing pharmaceutical companies for trying to shut down compounding pharmacies during drug shortages.
Context: The FDA has issued specific warnings about compounded GLP-1 drugs due to dosing errors, contamination risks, and adverse events. Eli Lilly’s lawsuit against ReviveRx specifically concerns unauthorized compounded versions of their tirzepatide medication (Mounjaro/Zepbound). By December 2024, the FDA removed tirzepatide from the shortage list, making compounding legally questionable.
Senate Testimony Presented Without Context
Buhler discusses his September 2024 Senate testimony on chronic disease, presenting himself as an expert advocate for healthcare reform. The episode fails to mention that Buhler’s business model depends on selling the exact types of medications (compounded GLP-1s, hormone therapies, peptides) that he testified about before Congress.
This is a clear financial conflict of interest that should have been disclosed and discussed.
Fact-Checks and Rebuttals
FDA Recall Documentation
The FDA’s recall enforcement report from April 2024 confirms ReviveRx mislabeled Tirzepatide vials that actually contained testosterone cypionate. This is documented in official FDA records and legal case filings.
Source: FDA Recall Enforcement Report, April 20, 2024; De La Garza Law analysis of Revive RX mislabeling incident.
FDA Inspection Report
FDA Form 483 issued to Revive Rx LLC dba Revive Rx Pharmacy in Houston, TX documented insanitary conditions during a May 4, 2022 inspection. The report is available through FDA.gov official records.
Source: FDA Form 483, Revive Rx LLC, Houston, TX, issued 02/07/2025 (referencing May 2022 inspection).
Compounding Pharmacy Regulation
While Buhler portrays compounding pharmacies as heavily regulated and inspected, the reality is more complex. Compounding pharmacies are regulated by state boards of pharmacy, and FDA oversight is limited compared to traditional drug manufacturers. The FDA can inspect compounding pharmacies but has faced criticism for insufficient enforcement.
The fact that ReviveRx was able to distribute mislabeled medications for an unknown period before the recall was initiated demonstrates gaps in the oversight system Buhler claims provides adequate protection.
Source: FDA guidance on compounding pharmacies; Liles Parker legal analysis of GLP-1 compounding regulations.
Eli Lilly Lawsuit Legitimacy
While Buhler frames pharmaceutical company lawsuits against compounding pharmacies as predatory attempts to maintain monopolies, the legal issues are substantive. Eli Lilly’s September 2023 lawsuit against ReviveRx and other compounding pharmacies alleges:
- Trademark violations
- False advertising
- Selling compounded biologics that require FDA approval as new drugs
- Violations of state pharmacy laws in multiple jurisdictions
These are not frivolous claims - they involve fundamental questions about whether compounding pharmacies can legally produce versions of complex biologics that are under patent protection.
Source: Eli Lilly And Company v. Revive RX, LLC, Case No. 4:23-cv-03521, Texas Southern District Court; multiple pharmaceutical industry news sources.
Conclusion
This episode exemplifies a dangerous pattern in Joe Rogan’s podcast: presenting business owners with financial conflicts of interest as disinterested whistleblowers, without disclosing critical information that would help listeners evaluate their credibility.
Brigham Buhler may have legitimate criticisms of the pharmaceutical industry - many people do. However, his own track record includes:
- A Class I FDA recall for mislabeled medications that could cause death
- FDA documentation of unsanitary conditions at his facility
- Active litigation from pharmaceutical companies
- Financial incentives to promote compounding as superior to regulated pharmaceuticals
None of this context was provided during a three-hour podcast that allowed Buhler to testify about healthcare corruption before an audience of millions.
The Real Issue: Listeners deserve to know when someone criticizing an industry has serious problems in their own business practices within that same industry. The mislabeling of testosterone as a diabetes medication is not a minor administrative error - it’s exactly the type of dangerous failure that regulatory oversight is designed to prevent.
This episode damages public health by undermining trust in pharmaceutical regulation while promoting a business owner whose own pharmacy has documented safety violations. It’s particularly harmful given the ongoing epidemic of compounded GLP-1 medications entering the market with varying quality control standards.
Rogan’s failure to research his guest’s background or ask critical questions about documented FDA violations represents a fundamental failure of journalistic responsibility.